Literature DB >> 26809873

Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Alessandro Mantovani1, Stefano Ballestri2, Amedeo Lonardo3, Giovanni Targher4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in many developed countries, affecting an estimated 30 % of the adult population. In this updated clinical review, we summarize the current knowledge regarding the strong association between NAFLD and the risk of coronary heart disease (CHD) and other functional, structural, and arrhythmic cardiac complications (e.g., left ventricular dysfunction, heart valve diseases and atrial fibrillation). We also briefly discuss the putative biological mechanisms linking NAFLD with these important extra-hepatic complications. To date, a large body of evidence has suggested that NAFLD is not simply a marker of CHD and other functional, structural, and arrhythmic cardiac complications, but also may play a part in the development and progression of these cardiac complications. The clinical implication of these findings is that patients with NAFLD may benefit from more intensive surveillance and early treatment interventions aimed at decreasing the risk of CHD and other cardiac and arrhythmic complications.

Entities:  

Keywords:  Cardiac arrhythmias; Cardiac disease; Cardiovascular disease; Heart valve diseases; Myocardial dysfunction; Nonalcoholic fatty liver disease

Mesh:

Year:  2016        PMID: 26809873     DOI: 10.1007/s10620-016-4040-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  166 in total

1.  Serum gamma-glutamyl transferase and risk of heart failure in the community.

Authors:  Ravi Dhingra; Philimon Gona; Thomas J Wang; Caroline S Fox; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

Review 2.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.

Authors:  Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant
Journal:  Atherosclerosis       Date:  2006-05-08       Impact factor: 5.162

4.  Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis.

Authors:  Stephen H Caldwell; Luiz Antonio R de Freitas; Sang H Park; Maria Lucia V Moreno; Jan A Redick; Christine A Davis; Barbee J Sisson; James T Patrie; Helma Cotrim; Curtis K Argo; Abdullah Al-Osaimi
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

5.  Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT).

Authors:  Satoshi Akabame; Masahide Hamaguchi; Ki-Ichiro Tomiyasu; Muhei Tanaka; Yoshiko Kobayashi-Takenaka; Koji Nakano; Yohei Oda; Toshikazu Yoshikawa
Journal:  Circ J       Date:  2008-04       Impact factor: 2.993

6.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Chisato Nagata; Jun Takeda; Hiroshi Sarui; Yutaka Kawahito; Naohisa Yoshida; Atsushi Suetsugu; Takahiro Kato; Junichi Okuda; Kazunori Ida; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 7.  The human gut microbiome: a review of the effect of obesity and surgically induced weight loss.

Authors:  Timothy E Sweeney; John M Morton
Journal:  JAMA Surg       Date:  2013-06       Impact factor: 14.766

8.  Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study.

Authors:  Pauliina Pisto; Merja Santaniemi; Risto Bloigu; Olavi Ukkola; Y Antero Kesäniemi
Journal:  BMJ Open       Date:  2014-03-20       Impact factor: 2.692

9.  Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study).

Authors:  Aki J Käräjämäki; Olli-Pekka Pätsi; Markku Savolainen; Y Antero Kesäniemi; Heikki Huikuri; Olavi Ukkola
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

Review 10.  Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences.

Authors:  Matteo Serino; Vincent Blasco-Baque; Simon Nicolas; Remy Burcelin
Journal:  Curr Cardiol Rep       Date:  2014-11       Impact factor: 2.931

View more
  25 in total

Review 1.  Cardiac abnormalities in patients with nonalcoholic fatty liver disease : Insights from auxiliary examinations.

Authors:  Yu Dong; Guangsen Li
Journal:  Herz       Date:  2019-09-19       Impact factor: 1.443

Review 2.  Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.

Authors:  Daniel Caldeira; Filipe B Rodrigues; Marta M Duarte; Carmelo Sterrantino; Márcio Barra; Nilza Gonçalves; Fausto J Pinto; Joaquim J Ferreira; João Costa
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

Review 3.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

Review 4.  Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?

Authors:  Yaron Ilan
Journal:  Dig Dis Sci       Date:  2018-04-20       Impact factor: 3.199

Review 5.  Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Raymond T Chung; Robert Giugliano
Journal:  Dig Dis Sci       Date:  2016-10-06       Impact factor: 3.199

6.  Managing the Burden of Non-NASH NAFLD.

Authors:  Christopher J Danford; Jorge E Sanchez; Kathleen E Corey
Journal:  Curr Hepatol Rep       Date:  2017-10-27

Review 7.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

Review 8.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.

Authors:  Amedeo Lonardo; Stefano Ballestri; Giovanni Guaraldi; Fabio Nascimbeni; Dante Romagnoli; Stefano Zona; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

9.  Correlations between the abdominal fat-related parameters and severity of coronary artery disease assessed by computed tomography.

Authors:  Yating Gao; Yuan-Cheng Wang; Chun-Qiang Lu; Chuhui Zeng; Di Chang; Shenghong Ju
Journal:  Quant Imaging Med Surg       Date:  2018-07

10.  The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study.

Authors:  Laura S Chiu; Alison Pedley; Joseph M Massaro; Emelia J Benjamin; Gary F Mitchell; David D McManus; Jayashri Aragam; Ramachandran S Vasan; Susan Cheng; Michelle T Long
Journal:  Liver Int       Date:  2020-07-25       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.